A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Sotagliflozin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms inTandem1
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 15 Sep 2017 Results analysing 24-week efficacy and safety of sotagliflozin, as adjunct therapy to insulin in type 1 diabetes patients, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
    • 08 Sep 2017 Results of pooled data from inTandem1 and inTandem2 studies published in the Media Release.
    • 05 Sep 2017 According to a Lexicon Pharmaceuticals media release, data from this study will be presented at the upcoming European Association for the Study of Diabetes (EASD) 53rd annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top